Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares fell 1.2% on Monday . The company traded as low as $60.14 and last traded at $61.33, with a volume of 176,639 shares changing hands. The stock had previously closed at $62.05.

A number of research firms recently weighed in on EGRX. Mizuho reiterated a “buy” rating and issued a $71.00 price objective on shares of Eagle Pharmaceuticals in a research note on Friday, May 6th. Royal Bank Of Canada reiterated a “buy” rating and issued a $78.00 price objective on shares of Eagle Pharmaceuticals in a research note on Monday, June 13th. TheStreet upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 9th. Finally, Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, July 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $88.94.

The company has a market capitalization of $948.48 million and a P/E ratio of 311.08. The stock has a 50-day moving average of $46.54 and a 200 day moving average of $47.86.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.09. The company had revenue of $40.90 million for the quarter, compared to the consensus estimate of $43.55 million. During the same quarter last year, the company earned ($0.53) EPS. The firm’s revenue for the quarter was up 581.7% on a year-over-year basis. Equities research analysts predict that Eagle Pharmaceuticals Inc. will post $3.34 EPS for the current fiscal year.

An institutional investor recently raised its position in Eagle Pharmaceuticals stock. Bank of Montreal Can increased its position in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) by 62.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 119,902 shares of the specialty pharmaceutical company’s stock after buying an additional 46,020 shares during the period. Bank of Montreal Can owned approximately 0.77% of Eagle Pharmaceuticals worth $10,632,000 at the end of the most recent reporting period.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.